Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Enzene Biosciences.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Enzene Biosciences
india-flag Flag
Country
Country
India
Address
Address
Plot Number 165/1/26, Opp Hotel Fern Residency, MIDC, Bhosari,, Pune, Maharashtra 411026
Telephone
Telephone
+912067184200
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Bevacizumab is a vascular endothelial growth factor inhibitor for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.


Lead Product(s): Bevacizumab

Therapeutic Area: Oncology Product Name: Avastin-Generic

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through collaboration, Lupin with Enzene will launch enz-124 (cetuximab) in India, the 1st biosimilar developed for Cetuximab, sold under the brand Erbitux. Cetuximab, a chimeric monoclonal antibody, is used as a targeted therapy for metastatic colorectal cancer and SCCHN.


Lead Product(s): Cetuximab

Therapeutic Area: Oncology Product Name: enz-124

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Lupin Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Adalimumab-bwwd is being launched for treating autoimmune disease like rheumatoid arthritis and ankylosis spondylitis. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface.


Lead Product(s): Adalimumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Theramex has entered into an agreement with Enzene Biosciences to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors.


Lead Product(s): Tocilizumab,Methotrexate

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Theramex

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 23, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY